Mergers & Acquisitions Mergers & Acquisitions

Comment: Thermo Fisher-Qiagen antitrust review likely to focus on sample preparation

By Flavia Fortes
  • 13 Mar 2020 15:22
  • 24 Mar 2020 09:32
The antitrust review of Thermo Fisher Scientific's proposed acquisition of genetic testing company Qiagen is likely to focus on the companies’ overlaps in sample preparation for next-generation sequencing, or NGS.

Medical technology company Thermo Fisher announced on March 3 its plans to buy Netherlands-based holding company Qiagen for $11.5 billion. Qiagen makes genetic-testing

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News